EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes

Melissa R Riester iD, Andrew R Zullo iD, Richa Joshi, Lori A Daiello, Kaleen N Hayes, Darae Ko, Dae Hyun Kim, Medha Munshi iD, Sarah D Berry

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15682 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Melissa R Riester und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Nursing Homes, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Studies examining the safety and effectiveness of sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) versus glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among community‐dwelling adults may not generalize to nursing home (NH) residents, who are typically older and more multimorbid. We compared the safety and cardiovascular effectiveness of SGLT2is and GLP‐1RAs among US NH residents. Materials and Methods Eligible individuals were aged ≥66 years with type 2 diabetes mellitus and initiated an SGLT2i or GLP‐1RA in an NH between 2013 and 2018. Safety outcomes included fall‐related injuries, hypoglycaemia, diabetic ketoacidosis (DKA), urinary tract infection or genital infection, and acute kidney injury in the year following treatment initiation. Cardiovascular effectiveness outcomes included death, major adverse cardiovascular events and hospitalization for heart failure. Per‐protocol adjusted hazard ratios (HR) were calculated using stabilized inverse probability of treatment and censoring weighted cause‐specific hazard regression models accounting for 127 covariates.

Results

The study population included 7710 residents (31.08% SGLT2i, 68.92% GLP‐1RA). Compared with GLP‐1RA initiators, SGLT2i initiators had higher rates of DKA (HR 1.95, 95% confidence limits 1.27, 2.99) and death (HR 1.18, 95% confidence limits 1.02, 1.36). Rates of urinary tract infection or genital infection, acute kidney injury, major adverse cardiovascular events, and heart failure were also elevated, while rates of fall‐related injuries and hypoglycaemia were reduced, but all estimates were imprecise and highly compatible with no difference.

Conclusions

SGLT2is do not have superior, and may have inferior, effectiveness compared with GLP‐1RAs for cardiovascular and mortality outcomes in NH residents. Residents initiating SGLT2is should be monitored closely for DKA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsNursing HomesDiabetes Mellitus, Type 2Cardiovascular DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHumansAgedFemaleMaleAged, 80 and overHypoglycemic AgentsTreatment OutcomeHypoglycemiaAcute Kidney Injury

Stichwörter der Autor:innen

effectivenessglucagon‐like peptide‐1observational studypharmaco‐epidemiologysodium‐glucose cotransporter‐2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
  • Center for Gerontology and Healthcare Research, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
  • Center of Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
  • Department of Neurology, Warren Alpert Medical School of Brown University, and Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital, Providence, Rhode Island, USA.
  • Graduate Department of Pharmaceutical Sciences, University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada.
  • Hinda and Arthur Marcus Institute for Aging Research and Department of Medicine, Hebrew SeniorLife, Boston, Massachusetts, USA.

ORCID-Profile: Melissa R Riester, Andrew R Zullo, Medha Munshi

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Riester, M. R., Zullo, A. R., Joshi, R., Daiello, L. A., Hayes, K. N., Ko, D., Kim, D. H., Munshi, M., & Berry, S. D. (2024). Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15682

Vancouver

Riester MR, Zullo AR, Joshi R, Daiello LA, Hayes KN, Ko D, et al. Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15682

BibTeX
@article{Riester2024,
  author = {Riester, Melissa R and Zullo, Andrew R and Joshi, Richa and Daiello, Lori A and Hayes, Kaleen N and Ko, Darae and Kim, Dae Hyun and Munshi, Medha and Berry, Sarah D},
  title = {Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15682}
}
Kostenlos starten →